{"text": "Only patients with symptom duration of less than 2 years at baseline visit , who were still alive at the time of the third assessment , were eligible for this analysis .", "label": "", "metadata": {}, "score": "28.211653"}
{"text": "A total of -22 patients in the exercise therapy group and 31 patients in the control group went through THR within the 3.6 - 6.1 years follow - up period .", "label": "", "metadata": {}, "score": "33.237907"}
{"text": "However , some individual patients in the reference control group showed equally marked improvements at particular points during the course of their 6-monthly , or annual assessments ( see figure 1 ) .", "label": "", "metadata": {}, "score": "33.261497"}
{"text": "At the 16-month follow - up , 75 patients replied to the questions on exercise and physical therapy , and at the 29-month follow - up 70 patients replied ( table 3 ) .", "label": "", "metadata": {}, "score": "33.322987"}
{"text": "The studies were sham - controlled through Month 24 .Patient age ranged from 21 to 91 years , with a mean age of 62 years .", "label": "", "metadata": {}, "score": "34.33627"}
{"text": "The remaining six patients were treated as censored at the time of last follow - up or contact during the follow - up period .Patients who were censored before the end of study did not differ at baseline from those attending the long - term follow - up .", "label": "", "metadata": {}, "score": "34.822166"}
{"text": "Subjects who had experienced at least one period of remission according to definition 1 within the first 3 years of follow - up showed a 27 % relative reduction in the risk of all - cause mortality ( HR 0.73 ( 95 % CI 0.56 to 0.94 ) ) .", "label": "", "metadata": {}, "score": "34.823067"}
{"text": "We found that the achievement of remission within the first 3 years from the diagnosis was associated with a fall of about 30 % in the risk of all - cause mortality thereafter .", "label": "", "metadata": {}, "score": "34.825882"}
{"text": "6 - 8 These studies reported motor and cognitive improvements and stabilisation over 5 - 6 years , consistent with data from positron emission tomography ( PET ) scans showing striatal metabolic activity at the site of graft placement .", "label": "", "metadata": {}, "score": "36.085342"}
{"text": "All the neurological measures and all but one of the neuropsychological measures yielded a highly significant change across the years , as has been reported previously for non - surgical patients from this cohort over a 3 - 6-year time span .", "label": "", "metadata": {}, "score": "37.051575"}
{"text": "In sensitivity analyses , less stringent definitions of remission were used , based on 28-joint counts .Remission was assessed at 1 , 2 and 3 years after baseline .", "label": "", "metadata": {}, "score": "37.594906"}
{"text": "A total of 550 patients were enrolled in the two 0.5 mg treatment groups with 467 ( 85 % ) completing through Month 24 .Data are available through Month 24 .", "label": "", "metadata": {}, "score": "38.48814"}
{"text": "The present study is similarly open label , and none of the testing was undertaken blind .Rather , the motor and cognitive features progressed at a very similar rate over the subsequent 8 - 10 years in both groups .", "label": "", "metadata": {}, "score": "38.783066"}
{"text": "Also , 27 patients had gone through THR prior to the 29-month follow - up and 11 patients were lost to follow - up at the 29-month follow - up .", "label": "", "metadata": {}, "score": "39.138184"}
{"text": "Treatment repeat every 21 days for up to 12 courses .Quality of life is assessed at baseline , before courses 4 , 7 , and 10 , and then after completion of study treatment .", "label": "", "metadata": {}, "score": "39.273727"}
{"text": "One hundred and nine patients were included in the trial and randomised to the exercise therapy group or the control group ( figure 1 ) .", "label": "", "metadata": {}, "score": "39.39079"}
{"text": "Compare objective response in patients with measurable disease treated with these regimens .Determine whether a 30 % reduction in PSA and the slope of PSA from baseline to 3 months is a surrogate marker for survival in patients treated with these regimens .", "label": "", "metadata": {}, "score": "39.574448"}
{"text": "The overall rates of progression from baseline to 1 year after the second operation were similar on both sides , and were not significantly different from those of non - grafted HD controls ( figure 2 ) , in line with previous longitudinal studies in HD using this ligand .", "label": "", "metadata": {}, "score": "39.79908"}
{"text": "In Studies D-1 and D-2 , patients received monthly injections of LUCENTIS for 12 or 36 months , after which 500 patients opted to continue in the long - term follow - up study .", "label": "", "metadata": {}, "score": "40.101288"}
{"text": "Discussion .There were no significant differences in any of the measures chosen when comparing patients with transplants with this reference cohort at baseline and followed - up for up to 10 years postsurgery , using identical protocols of assessment .", "label": "", "metadata": {}, "score": "40.436203"}
{"text": "By the third year anniversary , 73.1 % of patients had fulfilled the ACR criteria and 57.8 % had been treated with a DMARD .As expected , less stringent definitions led to increasing occurrence of remission , ranging from 30.7 % of patients achieving remission at least once during the first 3 years according to definition 1 to 54.1 % according to definition 3 ( see online supplementary table S1 ) .", "label": "", "metadata": {}, "score": "41.78712"}
{"text": "Patients received LUCENTIS 0.3 mg or 0.5 mg intravitreal injections or sham injections once a month for 3 consecutive doses , followed by a dose administered once every 3 months for 9 months .", "label": "", "metadata": {}, "score": "41.900585"}
{"text": "[ Time Frame : 64 weeks ] [ Designated as safety issue : Yes ] .Change from Baseline to various time points throughout the study in the Brief Pain Inventory Short Form ( BPI sf ) pain scores , Pain Interference with Function Composite Score , and Pain Interference subscales .", "label": "", "metadata": {}, "score": "42.450268"}
{"text": "The first five patients were all selected for grafting from the Cambridge cohort of 17 patients recruited into the CAPIT - HD longitudinal assessment program .", "label": "", "metadata": {}, "score": "42.81723"}
{"text": "Using multiple imputation ( 20 datasets ) of remission variables and confounders , 1251 subjects were available for all the adjusted analyses .Starting from the third year of observation , over a median follow - up of 7.93 years ( IQR 4.7 - 14.8 ) , corresponding to 12 030 person - years , 348/1251 ( 26.5 % ) deaths occurred .", "label": "", "metadata": {}, "score": "43.04773"}
{"text": "During study period ( up to 20 months ) ] [ Designated as safety issue : No ] .Radiographic progression - free survival was defined as the time from randomization to the first objective evidence of radiographic disease progression assessed by independent central radiology review or death due to any cause within 168 days after treatment discontinuation , whichever was first .", "label": "", "metadata": {}, "score": "44.310745"}
{"text": "Differences between these two groups have been previously reported .14 The second group comprised patients with longer mean symptom duration , higher disease activity , higher disability , but , probably due to a more intensive treatment strategy , a higher proportion of patients from the second group achieved a status of clinical remission .", "label": "", "metadata": {}, "score": "44.39063"}
{"text": "The number of patients at risk is given for each year for each group .Self - reported pain , stiffness and function .Self - reported physical activity and exercise .", "label": "", "metadata": {}, "score": "44.59524"}
{"text": "Data are available through Month 24 .Patients treated with LUCENTIS in Study AMD-2 received a mean of 21 total treatments out of a possible 24 from Day 0 through Month 24 .", "label": "", "metadata": {}, "score": "45.39505"}
{"text": "The five patients with transplants are compared with the remaining 12 patients recruited into the longitudinal NEST - HD cohort , and similarly available for selection for transplantation prior to trial suspension ( ' Reference control group ' ) .", "label": "", "metadata": {}, "score": "45.40659"}
{"text": "Compare elements of Quality of Life between treatment arms : change in functional status as measured by the Trial Outcome Index score from the FACT - P [ Time Frame : up to 18 months study period ] [ Designated as safety issue : No ] .", "label": "", "metadata": {}, "score": "45.85695"}
{"text": "The increasing number of times spent in remission showed an incremental effect on mortality .A recent study investigated the effect of sustained clinical remission ( 3 , 4 and 5 years after inclusion in an inception cohort ) according to DAS remission criteria on mortality in 704 patients with early RA .", "label": "", "metadata": {}, "score": "45.889626"}
{"text": "Patients treated with LUCENTIS in Study AMD-1 received a mean of 22 total treatments out of a possible 24 from Day 0 to Month 24 .", "label": "", "metadata": {}, "score": "46.03529"}
{"text": "In Studies D-1 and D-2 , patients received monthly LUCENTIS 0.3 mg or 0.5 mg intravitreal injections or monthly sham injections during the 24-month controlled treatment period .", "label": "", "metadata": {}, "score": "46.188263"}
{"text": "Weeks 25 - 48 : Bevacizumab 7.5 mg / kg was administered as an intravenous infusion over 30 minutes .Cycle length was 3 weeks .", "label": "", "metadata": {}, "score": "46.44023"}
{"text": "Weeks 25 - 48 : Bevacizumab 7.5 mg / kg was administered as an intravenous infusion over 30 minutes .Cycle length was 3 weeks .", "label": "", "metadata": {}, "score": "46.44023"}
{"text": "Patients were evaluable for PSA response rate if a patient had a PSA level measured at baseline and at least one postbaseline assessment .Best Overall Soft Tissue Response [ Time Frame :", "label": "", "metadata": {}, "score": "46.450783"}
{"text": "If the trial had been designed for this purpose , then a further 21 patients would be needed in the transplant arm to detect a clinically meaningful difference of five points on the Unified Huntington 's Disease Rating Scale ( UHDRS ) motor scale at 10 - 12 years postsurgery .", "label": "", "metadata": {}, "score": "46.557037"}
{"text": "Baseline Measures are based on the Intent - to - Treat - Stage III Disease Patient Population .Reporting Groups .Description . FOLFOX4 .Leucovorin 200 mg / m^2 ( alone ) , followed by 5-FU 400 mg / m^2 bolus injection , and 5-FU 600 mg / m^2 continuous infusion were repeated on day 2 .", "label": "", "metadata": {}, "score": "46.75392"}
{"text": "Patient must be able to comply with lifestyle guidelines , scheduled visits , treatment plan , laboratory tests , and other study procedures .Patient has been treated in a parent tanezumab double blind CLBP study .", "label": "", "metadata": {}, "score": "46.942345"}
{"text": "Patients treated with LUCENTIS in Study AMD-3 received a mean of 6 total treatments out of a possible 6 from Day 0 through Month 12 .", "label": "", "metadata": {}, "score": "46.9503"}
{"text": "Compliance was based on training diaries filled in weekly by the patients in the exercise therapy group during the 12-week intervention period .Attending at least 20 of a total of 24 sessions was defined as satisfactory adherence .", "label": "", "metadata": {}, "score": "47.126015"}
{"text": "From Month 3 through Month 24 , visual acuity decreased by 0.3 letters in the 0.5 mg less frequent dosing arm and increased by 0.7 letters in the 0.5 mg monthly arm ( see Figure 3 ) .", "label": "", "metadata": {}, "score": "47.21286"}
{"text": "Having been in remission at least once within the first 3 years of follow - up was associated with a significantly lower risk of death : HR 0.72 ( 95 % CI 0.55 to 0.94 ) .", "label": "", "metadata": {}, "score": "47.660896"}
{"text": "Having been in remission at least once within the first 3 years of follow - up was associated with a significantly lower risk of death : HR 0.72 ( 95 % CI 0.55 to 0.94 ) .", "label": "", "metadata": {}, "score": "47.660896"}
{"text": "Patient age ranged from 20 to 91 years , with a mean age of 67 years .A total of 789 patients ( LUCENTIS 0.3 mg , 266 patients ; LUCENTIS 0.5 mg , 261 patients ; sham , 262 patients ) were enrolled , with 739 ( 94 % ) patients completing through Month 6 .", "label": "", "metadata": {}, "score": "47.932358"}
{"text": "Long - term large observational studies are currently the most feasible study design in which to address this question .A recent multi - centre cohort study including 704 early RA patients explored the influence of sustained remission , measured by the Disease Activity Score ( DAS ) , 19 on all - cause mortality . 15", "label": "", "metadata": {}, "score": "48.31137"}
{"text": "All assessments were undertaken ' open label ' , without blinding of patients or clinicians to the treatment .Tissue preparation and neurosurgical procedures .Full details of tissue procurement , preparation , immunosuppression , safety assessment and implantation of the first four unilateral implants has been fully reported elsewhere .", "label": "", "metadata": {}, "score": "48.573547"}
{"text": "Results regarding the primary outcome measure of the trial , self - reported pain at 16 months follow - up , have been reported previously .", "label": "", "metadata": {}, "score": "48.684082"}
{"text": "Pain progression will continue to be evaluated through Step 2 .Required Palliative Radiotherapy .Compare qualitative and quantitative toxicity between the two study arms [ Time Frame : Assessed every 3 weeks up to 52 weeks ] [ Designated as safety issue : Yes ] .", "label": "", "metadata": {}, "score": "48.842514"}
{"text": "Overall Survival in Stage III Cancer Patients - Time to Event [ Time Frame : From first patient randomized until the clinical data cut - off date of 30 June 2010 ( 36 months after the last patient randomized ) . ]", "label": "", "metadata": {}, "score": "48.951134"}
{"text": "Progression of performance in the neuropsychological test battery was similarly analysed , combining each patient 's mean performance in 2-year blocks .By contrast to the conventional neuropsychological tests , we found the CANTAB automated touch screen measures to be less sensitive to the longitudinal progression of the disease ( see supplementary table 2 ) .", "label": "", "metadata": {}, "score": "48.957718"}
{"text": "Thus , Patient 1 showed improvement after the first unilateral transplant , with the UHDRS motor score falling from 37 to 18 in the first 6 months after transplantation .", "label": "", "metadata": {}, "score": "48.989365"}
{"text": "The study was designed as a learning rather than a confirming trial and , as such , sought to describe what was seen , rather than being powered to show an effect .", "label": "", "metadata": {}, "score": "48.997025"}
{"text": "Neurological assessments were conducted at 6-monthly intervals according to the CAPIT protocol .However , although it does appear that the group with transplants shows a slowing of impairment on this one test , the only significant difference relates to the last time point 10 - 12 years after initial recruitment 6 - 8 years postsurgery , and not in the period immediately following transplantation .", "label": "", "metadata": {}, "score": "49.420105"}
{"text": "This included patients who were known to have died after the data analysis cutoff date .Patients with no post - baseline survival information were censored on the date of randomization .", "label": "", "metadata": {}, "score": "49.642296"}
{"text": "Overall Survival [ Time Frame :During study period ( up to 3 years ) ] [ Designated as safety issue : No ] .Overall survival was defined as the time from randomization to death due to any cause .", "label": "", "metadata": {}, "score": "49.76435"}
{"text": "A preliminary report of safety of the surgical procedures has been published from the first four patients after unilateral transplantation .15 Following this , the second phase of the trial commenced , in which these patients received contralateral transplants , and one additional patient received simultaneous bilateral transplants .", "label": "", "metadata": {}, "score": "49.7705"}
{"text": "Overall Survival in Stage III Cancer Patients - Time to Event : Final Analysis [ Time Frame : From first patient randomized until the final data cut - off date of 30 June 2012 ( 5 years after the last patient randomized ) . ]", "label": "", "metadata": {}, "score": "49.83429"}
{"text": "The interacting variable identified six levels of progressively higher exposure to remission ( increasing number / decreasing timing ) : remission once at year 1 , 2 and 3 , remission twice with first remission at year 1 or 2 and three times in remission .", "label": "", "metadata": {}, "score": "50.023136"}
{"text": "Clinical assessment .All patients underwent a longitudinal assessment which included the full CAPIT - HD protocol 22 plus additional motor and cognitive assessments .The five patients with transplants had pre- and postsurgical MRI and raclopride PET scans .", "label": "", "metadata": {}, "score": "50.23947"}
{"text": "Patients undergo bone mineral density measurement by DEXA scan at baseline ( if not done within 12 months of study entry ) , at 24 and 48 months during study therapy , and at the completion of study therapy .", "label": "", "metadata": {}, "score": "50.36903"}
{"text": "For longitudinal analysis of progression in control patients , T0 was designated as 4 years following first recruitment into the programme ( although other arbitrary time shifts have no effect on the results ) .", "label": "", "metadata": {}, "score": "50.39382"}
{"text": "Patients who did not have a skeletal - related event at the time of the analysis data cutoff were censored at the date of last assessment indicating no evidence of skeletal - related event .", "label": "", "metadata": {}, "score": "50.75143"}
{"text": "Longitudinal progression of impairments on each neurological and neuropsychological test was analysed by a two - factor analyses of variance ( Genstat v.11 , VSN International , Hemel Hempstead ) .", "label": "", "metadata": {}, "score": "50.925888"}
{"text": "The response rate at follow - up was 94 % .The HR for survival of the native hip was 0.56 ( CI 0.32 to 0.96 ) for the exercise therapy group compared with the control group .", "label": "", "metadata": {}, "score": "50.990814"}
{"text": "At least eight weeks but no more than 12 weeks have elapsed since the last study medication infusion in the parent study .Patients are permitted to enter the extension study up to 12 weeks after their last dose of study medication in their parent study ( or 4 weeks after the End of Treatment visit ) .", "label": "", "metadata": {}, "score": "51.110085"}
{"text": "22 In our study , 40 % in the exercise therapy group and 57 % in the control group underwent THR , with the control group having 1.80 times higher probability of THR .", "label": "", "metadata": {}, "score": "51.35134"}
{"text": "All patients were eligible for macular focal / grid laser treatment beginning at Month 3 of the 24-month treatment period or panretinal photocoagulation ( PRP ) as needed .", "label": "", "metadata": {}, "score": "51.403774"}
{"text": "On average , CPT reductions were observed in Studies RVO-1 and RVO-2 beginning at Day 7 following the first LUCENTIS injection through Month 6 .CPT was not evaluated as a means to guide treatment decisions [ see Clinical Studies ] .", "label": "", "metadata": {}, "score": "51.59143"}
{"text": "Although not its primary aim , the present data provide what is probably the longest longitudinal study of functional progression in HD using standardised neurological and neuropsychological tests .", "label": "", "metadata": {}, "score": "51.795784"}
{"text": "The time to first remission was associated with a decreased risk of death .When first remission was not achieved until the third anniversary , no significant advantage in survival was noted ( adjHR 1.03 ( 95 % CI 0.95 to 1.12 ) ) .", "label": "", "metadata": {}, "score": "51.960148"}
{"text": "Restricted analyses to subgroups of patients showed a slightly higher reduction of the risk of death associated with remission in men , in patients fulfilling 1987 ACR criteria or ever treated with DMARDs ( see online supplementary table S2 ) .", "label": "", "metadata": {}, "score": "52.068253"}
{"text": "One patient discontinued exercise after three sessions due to increasing hip pain .No other adverse events were registered .Data on whether THR had been performed were obtained from 102 patients .", "label": "", "metadata": {}, "score": "52.1753"}
{"text": "Other studies have found beneficial short - term effects of exercise therapy .7 , 8 No significant difference in self - reported pain was demonstrated in the 16-month follow - up of our trial , but the patients in the exercise therapy group had better self - reported physical function compared with the control group .", "label": "", "metadata": {}, "score": "52.315628"}
{"text": "Patients with stable or responding disease after course 12 may register for continued oral placebo treatment for up to 52 weeks .Interventions : .Drug : docetaxel .", "label": "", "metadata": {}, "score": "52.346184"}
{"text": "Patients also receive oral atrasentan and oral prednisone once daily on days 1 - 21 .Treatment repeats every 21 days for up to 12 courses .", "label": "", "metadata": {}, "score": "53.082718"}
{"text": "No unequivocal progression of non - measurable disease .No new lesions .Compare elements of Quality of Life between treatment arms : pain palliation response , as measured by the Brief Pain Inventory ( BPI )", "label": "", "metadata": {}, "score": "53.10926"}
{"text": "On the other hand , these results indicate that a soft predictor such as a simple clinically based definition of remission is still able to discriminate between patients with different hard outcomes such as mortality .", "label": "", "metadata": {}, "score": "53.14424"}
{"text": "Kaplan - Meier survival estimates over the 6-year follow - up period .The black line represents the exercise therapy group , and the grey line represents the control group .", "label": "", "metadata": {}, "score": "53.146187"}
{"text": "Median time to event and 95 % confidence intervals could not be estimated due to the low number of events .Statistical Analysis 1 for Disease - free Survival in Stage III Cancer Patients - Time to Event .", "label": "", "metadata": {}, "score": "53.46833"}
{"text": "An average of 22.5 months after the first transplant , patients 1 , 2 , 3 and 4 had a second transplant to the contralateral striatum .", "label": "", "metadata": {}, "score": "53.72394"}
{"text": "Participating in both exercise therapy and patient education resulted in significantly higher 6-year cumulative survival of the native hip to THR compared with patient education only .", "label": "", "metadata": {}, "score": "53.786915"}
{"text": "Overall survival [ Time Frame : 8 years ] [ Designated as safety issue : No ] .Long - term clinical and laboratory safety of aromatase inhibitor therapy , particularly cardiovascular morbidity and mortality , changes in bone mineral density , incidence of all bone fractures , and common toxicities [ Time Frame : 8 years ] [ Designated as safety issue : Yes ] .", "label": "", "metadata": {}, "score": "54.060898"}
{"text": "The distribution of injections received in the less frequent dosing arm is shown in Figure 4 .Figure 3 : Mean Change in Visual Acuity from Baseline to Month 24 in Study AMD-4 .", "label": "", "metadata": {}, "score": "54.079758"}
{"text": "Additional details about the analysis , such as null hypothesis and power calculation : .Adjustments for multiplicity was done using a closed test procedure which tests for differences between all three treatment groups at the 5 % alpha level first .", "label": "", "metadata": {}, "score": "54.1338"}
{"text": "Time Frame .From first patient randomized until the data cut - off date of 30 June 2010 ( 36 months after the last patient randomized ) .", "label": "", "metadata": {}, "score": "54.15954"}
{"text": "As an adjunct we have followed a group of 12 patients without grafts from the same cohort for more than 10 years , who showed clear and consistent progression of disability over a longer time frame than has been systematically evaluated hitherto .", "label": "", "metadata": {}, "score": "54.377537"}
{"text": "Therefore , the question whether early achievement of a status of clinical remission might be associated with a significant decrease is still to be answered .", "label": "", "metadata": {}, "score": "54.40184"}
{"text": "Detailed results are shown in Table 3 , Table 4 , and Figure 1 below .Table 3 : Visual Acuity Outcomes at Month 12 and Month 24 in Study AMD-1 .", "label": "", "metadata": {}, "score": "54.59385"}
{"text": "A further difference is that it is only on several of the CANTAB subtests that effects of the neurosurgical treatment were seen to show any significant interactions in this trial .", "label": "", "metadata": {}, "score": "54.610577"}
{"text": "After completion of study therapy , patients are followed annually .Study Type ICMJE .Interventional .Study Phase .Phase 3 .Study Design ICMJE .", "label": "", "metadata": {}, "score": "54.84761"}
{"text": "Use of disease modifying antirheumatic drugs ( DMARDs ) and/or oral corticosteroids , including start and stop date , were also collected at each follow - up visit .", "label": "", "metadata": {}, "score": "54.912178"}
{"text": "A total of 1323 patients ( LUCENTIS 879 , control 444 ) were enrolled in the three studies .Studies AMD-1 and AMD-2 .In Study AMD-1 , patients with minimally classic or occult ( without classic ) CNV lesions received monthly LUCENTIS 0.3 mg or 0.5 mg intravitreal injections or monthly sham injections .", "label": "", "metadata": {}, "score": "54.975048"}
{"text": "Primary analysis consisted of investigating the association between the first definition of remission and all - cause mortality .The following individual remission states were tested as independent variables : ( 1 ) ' remission ever ' ; ( 2 ) ' remission score ' ; and ( 3 ) ' time to remission ' in separate Cox proportional hazard regression models .", "label": "", "metadata": {}, "score": "55.021088"}
{"text": "PROJECTED ACCRUAL : A total of 930 patients will be accrued for this study within 4 years .Study Type ICMJE .Interventional .Study Phase .", "label": "", "metadata": {}, "score": "55.13169"}
{"text": "Randomisation and treatment groups .All included patients were given three group sessions of a patient education programme developed for patients with hip OA .17 Thereafter they were randomised to either an exercise therapy group or a control group .", "label": "", "metadata": {}, "score": "55.3564"}
{"text": "8 The PET scanning protocol is as described previously .29 Six of the patients without transplants also received RAC PET and acted as the controls for the patients with transplants .", "label": "", "metadata": {}, "score": "55.512844"}
{"text": "After an initial increase in visual acuity ( following monthly dosing ) , on average , patients dosed once every 3 months with LUCENTIS lost visual acuity , returning to baseline at Month 12 .", "label": "", "metadata": {}, "score": "55.62256"}
{"text": "Weeks 25 - 48 : Observation only .FOLFOX4 + Bv .Leucovorin 200 mg / m^2 ( alone ) , followed by 5-FU 400 mg / m^2 bolus injection , and 5-FU 600 mg / m^2 continuous infusion are repeated on day 2 .", "label": "", "metadata": {}, "score": "55.88453"}
{"text": "Weeks 25 - 48 : Observation only .FOLFOX4 + Bv .Leucovorin 200 mg / m^2 ( alone ) , followed by 5-FU 400 mg / m^2 bolus injection , and 5-FU 600 mg / m^2 continuous infusion are repeated on day 2 .", "label": "", "metadata": {}, "score": "55.88453"}
{"text": "Full details of all tests are provided in both the supplementary materials ( information about participants drug regimes ( see online supplementary table S1 ) , psychiatric assessment and automated neuropsychological assessment on the CANTAB testing battery ( see online supplementary table S2 ) and in the methods section .", "label": "", "metadata": {}, "score": "55.89203"}
{"text": "The cumulative survival of the native hip was higher in the exercise therapy group from 1 year and throughout the follow - up period .This is the first study to evaluate whether exercise therapy affects the need for THR in patients with isolated hip OA .", "label": "", "metadata": {}, "score": "56.019188"}
{"text": "Approximately 20 % of the overall population had prior PRP .After monthly treatment with LUCENTIS 0.3 mg , the following clinical results were observed ( Table 7 ; Figure 7 ) : . D-1 .", "label": "", "metadata": {}, "score": "56.099648"}
{"text": "Leucovorin 200 mg / m^2 ( alone ) , followed by 5-FU 400 mg / m^2 bolus injection , and 5-FU 600 mg / m^2 continuous infusion were repeated on day 2 .", "label": "", "metadata": {}, "score": "56.14949"}
{"text": "Patients who die or have soft tissue progression without pain progression are censored at those events .Pain progression is defined as patients reporting an increase of at least two Worst Pain points , maintained for at least two consecutive assessments .", "label": "", "metadata": {}, "score": "56.493294"}
{"text": "Figure 2 : Mean Change in Visual Acuity from Baseline to Month 12 in Study AMD-3 .Study AMD-4 .Study AMD-4 was a randomized , double - masked , active treatment - controlled , two - year study designed to assess the safety and efficacy of LUCENTIS 0.5 mg administered monthly or less frequently than monthly in patients with neovascular AMD .", "label": "", "metadata": {}, "score": "56.51793"}
{"text": "Our findings in this explanatory study show that participating in a 12-week exercise therapy programme in addition to patient education can reduce the need for THR or postpone surgery in patients with hip OA .", "label": "", "metadata": {}, "score": "56.75802"}
{"text": "Patients will be classified as pain palliated or not palliated .Patients with a WPS of \" 0 \" will be defined as \" stable \" if their WPS remains \" 0 \" for Weeks 7 and 10 with no increase in analgesic use , but they will not be categorized as responders .", "label": "", "metadata": {}, "score": "56.778034"}
{"text": "The influence of the following treatment variables was also evaluated : previous and/or concurrent treatment with DMARDs ( dichotomous ) ; DMARD duration ( tertiles ) ; and concurrent steroids ( dichotomous ) .", "label": "", "metadata": {}, "score": "56.805603"}
{"text": "Analyses were performed by IBM SPSS Statistics , V.19.0 ( IBM Corp. , Somers , New York , USA ) .Results .Characteristics of the patients .", "label": "", "metadata": {}, "score": "56.913956"}
{"text": "On average , CPT reductions were observed in Studies D-1 and D-2 beginning at Day 7 following the first LUCENTIS injection through Month 36 .CPT data did not provide information useful in influencing treatment decisions [ see Clinical Studies ] .", "label": "", "metadata": {}, "score": "56.976524"}
{"text": "At Month 6 , after monthly treatment with 0.5 mg LUCENTIS , the following clinical results were observed : .Table 5 : Visual Acuity Outcomes at Month 6 in Study RVO-1 and Study RVO-2 .", "label": "", "metadata": {}, "score": "57.220947"}
{"text": "The fifth patient received simultaneous bilateral striatal allografts in 2003 .Characteristics of both the individual patients with transplants and of the reference cohort are shown in table 1 .", "label": "", "metadata": {}, "score": "57.26025"}
{"text": "For patients who did not have confirmed PSA progression at the time of the analysis data cutoff , time to PSA progression was censored at the date of the last PSA assessment showing no evidence of confirmed PSA progression or the analysis data cutoff date , whichever was first .", "label": "", "metadata": {}, "score": "57.313637"}
{"text": "OUTLINE : This is a multicenter study .Patients are randomized to 1 of 2 treatment arms .Arm I : Patients receive oral letrozole once daily for up to 5 years in the absence of unacceptable toxicity , disease recurrence , or development of a second malignancy .", "label": "", "metadata": {}, "score": "57.475273"}
{"text": "Disease - free Survival in Stage III Cancer Patients - Time to Event [ Time Frame : From first patient randomized until the data cut - off date of 30 June 2010 ( 36 months after the last patient randomized ) . ]", "label": "", "metadata": {}, "score": "57.502243"}
{"text": "Methods Consecutive early IP patients , recruited to a primary care based inception cohort from 1990 to 1994 and from 2000 to 2004 were eligible for this study .", "label": "", "metadata": {}, "score": "57.81543"}
{"text": "The randomisation sequence was concealed from the study collaborators until treatment was assigned .The exercise therapy programme was specifically designed for patients with hip OA 18 and consisted of strengthening , flexibility and functional exercises .", "label": "", "metadata": {}, "score": "57.85782"}
{"text": "Statistical analysis .Patients were followed until time of THR in the index joint or until death , drop - out or end of study .", "label": "", "metadata": {}, "score": "57.92855"}
{"text": "This study sought to determine the predictive value of a pragmatic definition of remission on all - cause mortality in a primary care based inception cohort of patients with IP .", "label": "", "metadata": {}, "score": "57.951714"}
{"text": "No significant differences were found over time between the patients , grafted and non - grafted , on any subscore of the Unified Huntington 's Disease Rating Scale , nor on the Mini Mental State Examination .", "label": "", "metadata": {}, "score": "58.24511"}
{"text": "Patient five received a bilateral transplant and is still being followed - up 6 years after his operation .Details of drug treatments and performance on assessments additional to the CAPIT - HD protocol are included in the supplementary data .", "label": "", "metadata": {}, "score": "58.347797"}
{"text": "Pisters et al 22 found no long - term differences in pain and function when comparing individually tailored exercises and usual care , but suggested that patients who underwent THR may have biased the results .", "label": "", "metadata": {}, "score": "58.42141"}
{"text": "Time to Initiation of Cytotoxic Chemotherapy [ Time Frame :During study period ( up to 3 years ) ] [ Designated as safety issue : No ] .", "label": "", "metadata": {}, "score": "58.68528"}
{"text": "Provenance and peer review Not commissioned ; externally peer reviewed .References .Quantitative target values of predictors of mortality in rheumatoid arthritis as possible goals for therapeutic interventions : an alternative approach to remission or ACR20 responses ?", "label": "", "metadata": {}, "score": "58.758476"}
{"text": "Patients with stable or responding disease after course 12 may register for continued oral atrasentan treatment for up to 52 weeks .Interventions : .Drug : atrasentan hydrochloride .", "label": "", "metadata": {}, "score": "58.92972"}
{"text": "All patients were flagged with the national death register .Censoring was set at 1 May 2011 .The effect of remission on mortality was analysed using the Cox proportional hazard regression model , and presented as HRs and 95 % CIs .", "label": "", "metadata": {}, "score": "58.97264"}
{"text": "Placebo Comparator : Arm II .Patients receive oral placebo once daily for up to 5 years in the absence of unacceptable toxicity , disease recurrence , or development of a second malignancy .", "label": "", "metadata": {}, "score": "59.11502"}
{"text": "The exercise therapy group had better self - reported hip function prior to THR or end of study , but no significant differences were found for pain and stiffness .", "label": "", "metadata": {}, "score": "59.245453"}
{"text": "Tanezumab 20 mg administered IV every 8 weeks for 3 administrations followed by SC administration every 8 weeks for 4 administrations over a period of 64 weeks .", "label": "", "metadata": {}, "score": "59.27664"}
{"text": "At inclusion all patients were instructed to report if and when they went through THR surgery during the project period .Additionally , data on THR were recorded at follow - ups 4 , 10 , 16 and 29 months after inclusion and by contacting all patients by telephone in April and May 2011 ( figure 1 ) .", "label": "", "metadata": {}, "score": "59.414135"}
{"text": "As such , the present data fails to support the efficacy of the current transplantation protocol in significantly modifying the course of patients ' disease .", "label": "", "metadata": {}, "score": "59.800953"}
{"text": "Surgical and donor tissue parameters are shown in table 2 .Doses of the three immunosuppressant drugs were slowly withdrawn a year after the second transplant .", "label": "", "metadata": {}, "score": "59.801743"}
{"text": "Tanezumab 10 mg administered IV every 8 weeks for 3 administrations followed by SC administration every 8 weeks for 4 administrations over a period of 64 weeks .", "label": "", "metadata": {}, "score": "59.876244"}
{"text": "Improvements from baseline in DR severity as assessed on fundus photography were observed in Studies D-1 and D-2 at Month 3 ( first scheduled DR photographic assessment after randomization ) through Month 36 [ see Clinical Studies ] .", "label": "", "metadata": {}, "score": "59.92604"}
{"text": "Importantly , there is also no evidence of a detectable placebo effect in the transplant group when using objective motor ratings in the UHDRS , even though this is an open label trial design .", "label": "", "metadata": {}, "score": "60.01767"}
{"text": "Trial design .Following discussion and endorsement with the Cambridge research ethics committee , we adopted the following patient selection protocol .Within the Cambridge cohort of 17 patients , five patients were randomly selected to receive a transplant .", "label": "", "metadata": {}, "score": "60.112823"}
{"text": "[ Time Frame : Up to 7 years after study opens ] [ Designated as safety issue : No ] .Measured from date of registration to date of death due to any cause .", "label": "", "metadata": {}, "score": "60.15032"}
{"text": "This is in keeping with other published studies suggesting that early response is associated with a lower mortality risk , as well as a lower risk of other relevant long - term outcomes including joint damage and disability .", "label": "", "metadata": {}, "score": "60.198433"}
{"text": "[ Time Frame : 8 years ] [ Designated as safety issue : No ] .Original Secondary Outcome Measures ICMJE ( submitted : September 17 , 2008 ) .", "label": "", "metadata": {}, "score": "60.224457"}
{"text": "This supports the assumption that the patients who undergo THR surgery have more severe symptoms and functional limitations .Also , the patients who went through THR had smaller minimum joint space at baseline .", "label": "", "metadata": {}, "score": "60.25708"}
{"text": "This was first observed in some human striatal xenografts in the rat brain , 16 but has also been seen in at least two clinical trials in HD patients . 13 , 32 , 33 In our first study of safety and feasibility , we therefore undertook implants of relatively small amounts of tissues - typically 5 - 10\u00d710 6 cells from two or occasionally three ganglionic eminences from one or two donor embryos .", "label": "", "metadata": {}, "score": "60.34019"}
{"text": "However , as a tolerability trial , we started with a low number of cells implanted , similar to the strategy adopted in dose escalation studies of novel pharmacotherapeutics , and since the imaging revealed no obvious graft masses , the absence of efficacy is not remarkable .", "label": "", "metadata": {}, "score": "60.424934"}
{"text": "Almost all LUCENTIS - treated patients ( approximately 95 % ) maintained their visual acuity .Among LUCENTIS - treated patients , 31 % to 37 % experienced a clinically significant improvement in vision , defined as gaining 15 or more letters at 12 months .", "label": "", "metadata": {}, "score": "60.46231"}
{"text": "For the outcome measures of physical activity and exercise , mean ( SD ) or number was calculated , and a linear mixed model was used to compare PASE scores between the exercise therapy group and the control group .", "label": "", "metadata": {}, "score": "60.589058"}
{"text": "Median age at inclusion in the cohort was 57.1 years ( IQR 46.6 - 68.5 ) , with two - thirds being women .The median duration of symptoms at registration was 5.7 months ( IQR 3.1 - 10.1 ) .", "label": "", "metadata": {}, "score": "60.641922"}
{"text": "Drug : Placebo .Participants received placebo , administered as four capsules , once per day by mouth .Study drug treatment continued until disease progression ( evidence of radiographic progression , a skeletal - related event , or clinical progression ) and the initiation of a cytotoxic chemotherapy or an investigational agent , unacceptable toxicity , or withdrawal .", "label": "", "metadata": {}, "score": "60.70346"}
{"text": "Remission according to less stringent definitions was associated with progressively lower protective effect .Conclusions Early and sustained remission is associated with decreased all - cause mortality in patients with IP .", "label": "", "metadata": {}, "score": "60.79305"}
{"text": "Remission according to less stringent definitions was associated with progressively lower protective effect .Conclusions Early and sustained remission is associated with decreased all - cause mortality in patients with IP .", "label": "", "metadata": {}, "score": "60.79305"}
{"text": "This study was conducted with the approval of the Norfolk and Norwich University Hospital Local Research Ethics Committee .All subjects gave written consent .Demographic and clinical assessments .", "label": "", "metadata": {}, "score": "60.861744"}
{"text": "In Study RVO-1 , patients with macular edema following branch or hemi- RVO , received monthly LUCENTIS 0.3 mg or 0.5 mg intravitreal injections or monthly sham injections for 6 months .", "label": "", "metadata": {}, "score": "61.17128"}
{"text": "[ Time Frame : Up to 52 weeks ] [ Designated as safety issue : No ] .Complete Response ( CR ) : Complete disappearance of all measurable and non - measurable disease .", "label": "", "metadata": {}, "score": "61.216717"}
{"text": "In this study , CPT data did not provide information useful in influencing treatment decisions [ see Clinical Studies ] .In Study AMD-4 , CFT was assessed by spectral domain ( SD)-OCT in all patients ; on average , CFT reductions were observed beginning at Day 7 following the first LUCENTIS injection through Month 24 .", "label": "", "metadata": {}, "score": "61.55657"}
{"text": "In animal studies , following intravitreal injection , ranibizumab was cleared from the vitreous with a half - life of approximately 3 days .After reaching a maximum at approximately 1 day , the serum concentration of ranibizumab declined in parallel with the vitreous concentration .", "label": "", "metadata": {}, "score": "61.651207"}
{"text": "Methods .Study design and patients .This is a long - term follow - up of a randomised , controlled trial evaluating the effect of exercise therapy and patient education in patients with hip OA .", "label": "", "metadata": {}, "score": "61.88592"}
{"text": "Experimental : Arm I .Patients receive oral letrozole once daily for up to 5 years in the absence of unacceptable toxicity , disease recurrence , or development of a second malignancy .", "label": "", "metadata": {}, "score": "61.894623"}
{"text": "Patients who did not reach the endpoint were censored at their last assessment .Original Primary Outcome Measures ICMJE ( submitted : September 30 , 2010 ) .", "label": "", "metadata": {}, "score": "61.925385"}
{"text": "22 They found that 20 % underwent THR in the individually tailored exercise therapy group compared with 45 % in the usual care group for those with hip OA .", "label": "", "metadata": {}, "score": "61.983925"}
{"text": "Patients who were randomized into the parent study in violation of inclusion or exclusion criteria but who were not withdrawn from the parent study ; .", "label": "", "metadata": {}, "score": "62.042686"}
{"text": "Explanation of how the number of participants for analysis was determined .Includes whether analysis was per protocol , intention to treat , or another method .", "label": "", "metadata": {}, "score": "62.042862"}
{"text": "Compare pain progression of patients treated with these regimens .Compare the qualitative and quantitative toxicity of these regimens in these patients .Compare the quality of life , in terms of palliation of metastatic bone pain and improvement in functional status , of patients treated with these regimens .", "label": "", "metadata": {}, "score": "62.06523"}
{"text": "This resolved when the treatment was eventually discontinued .Immunosuppression was also thought to be responsible for a transient anaemia in Patients 1 and 3 , which again resolved on stopping the medication .", "label": "", "metadata": {}, "score": "62.126717"}
{"text": "XELOX+Bv .Weeks 25 - 48 : Bevacizumab 7.5 mg / kg was administered as an intravenous infusion over 30 minutes .Cycle length was 3 weeks .", "label": "", "metadata": {}, "score": "62.242226"}
{"text": "XELOX+Bv .Weeks 25 - 48 : Bevacizumab 7.5 mg / kg was administered as an intravenous infusion over 30 minutes .Cycle length was 3 weeks .", "label": "", "metadata": {}, "score": "62.242226"}
{"text": "Female patients must meet one of the following criteria : .Male patients must agree that they and their female spouses / partners will use adequate contraception ( 2 forms of birth control , one of which must be barrier method ) or be of non childbearing potential .", "label": "", "metadata": {}, "score": "62.289307"}
{"text": "They did not have access to the exercise therapy programme during the intervention period .Outcome measures and follow - up .Characteristics of the patients ' included age , gender , height , weight , work status , education level , unilateral or bilateral hip pain , pain duration , minimum joint space and Harris Hip Score .", "label": "", "metadata": {}, "score": "62.29435"}
{"text": "The safety and efficacy of LUCENTIS were assessed in two randomized , double - masked , 1-year studies in patients with macular edema following RVO .", "label": "", "metadata": {}, "score": "62.382103"}
{"text": "For patients who did not start cytotoxic chemotherapy at the time of the analysis data cutoff , time to initiation of cytotoxic chemotherapy was censored at the date of last assessment where no cytotoxic chemotherapy was indicated or at the analysis data cutoff date , whichever was first .", "label": "", "metadata": {}, "score": "62.437416"}
{"text": "( O table 4 and see online supplementary table S2 ) .Further adjustment for DMARDs duration and steroid use did not modify the estimated HR for remission ( 0.73 ( 95 % CI 0.56 to 0.95 ) ) .", "label": "", "metadata": {}, "score": "62.524292"}
{"text": "Current Secondary Outcome Measures ICMJE ( submitted : February 24 , 2014 ) .Compare pain progression between the two study arms .[ Time Frame : Up to 52 weeks ] [ Designated as safety issue : No ] .", "label": "", "metadata": {}, "score": "62.568695"}
{"text": "Pain palliation is the proportion of patients showing a two - point reduction in the Worst Pain score ( WPS ) maintained for two consecutive assessments with no increase in analgesic use .", "label": "", "metadata": {}, "score": "62.575867"}
{"text": "Investigating the specific association of each definition of remission , we found that the greatest weight was due to the fulfilment of the most stringent definition .", "label": "", "metadata": {}, "score": "62.74952"}
{"text": "This patient has never received any drug treatment for her chorea .Patient 2 also improved his motor score after the first transplant and again after the second operation , and for the next 6 years their motor UHDRS score seemed to stabilise .", "label": "", "metadata": {}, "score": "62.753376"}
{"text": "No .Population Description .Explanation of how the number of participants for analysis was determined .Includes whether analysis was per protocol , intention to treat , or another method .", "label": "", "metadata": {}, "score": "63.182568"}
{"text": "The primary population for efficacy analyses was the intent to treat population ( ITT ; all randomized patients ) with stage III disease .Reporting Groups .", "label": "", "metadata": {}, "score": "63.293095"}
{"text": "However , no significant graft deposits could be identified on serial imaging , using either MRI or RAC - PET .These observations are consistent with our previous experience with similar small graft volume protocols in rats and primates in which the implanted tissue volume was too small to exert any clear functional benefit .", "label": "", "metadata": {}, "score": "63.394455"}
{"text": "Sequentially numbered , sealed envelopes were used to assign treatment for patients consecutively by a research coordinator not involved in the patient assessment or interventions .", "label": "", "metadata": {}, "score": "63.46376"}
{"text": "Results .Out of a total of 1404 subjects eligible , 1251 subjects ( 89.1 % ) with complete joint count data at each time point were included in this analysis .", "label": "", "metadata": {}, "score": "63.553577"}
{"text": "While no sustained functional benefit was seen , we conclude that this may relate to the small amount of tissue that was grafted in this safety study compared with other reports of more successful transplants in patients with HD .", "label": "", "metadata": {}, "score": "63.93948"}
{"text": "Total hip replacement rate in a cohort of patients affected by symptomatic hip osteoarthritis following intra - articular sodium hyaluronate ( MW 1,500 - 2,000 kDa ) ORTOBRIX study .", "label": "", "metadata": {}, "score": "63.971935"}
{"text": "A linear mixed model was also applied to compare WOMAC scores prior to THR surgery or end of study between patients who went through THR and patients who did not .", "label": "", "metadata": {}, "score": "64.024"}
{"text": "Worse self - reported pain and functional limitations are associated with a higher THR rate , 31 but can not be used to discriminate between patients who are or are not in need of a THR as clinical severity varies widely .", "label": "", "metadata": {}, "score": "64.07289"}
{"text": "At Month 24 , after monthly treatment with LUCENTIS 0.3 mg , the following clinical results were observed : .VA outcomes observed at Month 24 in patients treated with LUCENTIS 0.3 mg were maintained with continued treatment through Month 36 in both DME studies .", "label": "", "metadata": {}, "score": "64.10442"}
{"text": "The mean time from inclusion till the end of study at 15 May 2011 was 4.8 years , ranging from 3.6 to 6.1 years .The Western Ontario and McMaster Universities Osteoarthritis Index ( WOMAC ) 19 and the Physical Activity Scale for the Elderly ( PASE ) 20 were filled in at baseline and at the 4- , 10- , 16- and 29-month follow - up .", "label": "", "metadata": {}, "score": "64.17327"}
{"text": "The remaining 202 patients were followed for less than 12 months .Diabetic Retinopathy In patients With Diabetic Macular Edema ( DME ) .Efficacy and safety data of LUCENTIS are derived from studies D-1 and D-2 ( See Section on Diabetic Macular Edema above ) .", "label": "", "metadata": {}, "score": "64.19951"}
{"text": "Full details of the methods can be found in Rosser et al , 15 , 17 briefly given in what follows .Patient cohort .Initial plans for fetal cell transplantation in HD originated from the European Biomed network for striatal transplantation in HD ( NEST - HD ) in 1990 - 1993 .", "label": "", "metadata": {}, "score": "64.58446"}
{"text": "However , the data on physical activity , exercise and physical therapy treatment suggest that no major between - group differences were present .Self - reported outcome measures lack validity for measuring physical activity and exercise due to recall bias and overestimation of time , frequency and intensity , 33 and these data should therefore be interpreted with caution .", "label": "", "metadata": {}, "score": "64.60945"}
{"text": "PSA Partial Response : Greater than or equal to 50 % reduction in baseline PSA .There must be no evidence of soft tissue progression , or confirmed none disease progression , or pain progression .", "label": "", "metadata": {}, "score": "64.921074"}
{"text": "Clinical examination of the breast area , axillae , and neck within the past 60 days .Chest x - ray within the past 60 days .", "label": "", "metadata": {}, "score": "64.94322"}
{"text": "Overall survival [ Designated as safety issue : No ] .Long - term clinical and laboratory safety of aromatase inhibitor therapy , particularly cardiovascular morbidity and mortality , changes in bone mineral density , incidence of all bone fractures , and common toxicities [ Designated as safety issue : Yes ] .", "label": "", "metadata": {}, "score": "64.972786"}
{"text": "Efficacy and safety data of LUCENTIS are derived from studies D-1 and D-2 ( See Section on Diabetic Retinopathy below ) .All enrolled patients had DR and DME at baseline .", "label": "", "metadata": {}, "score": "65.0168"}
{"text": "22The British version of the Health Assessment Questionnaire ( HAQ ) was completed by the patients at baseline and annually thereafter .23 Blood samples were taken and frozen to determine RF ( latex test ) , anticitrullinated protein antibody status ( Axis - Shield Diastat Anti - CCP kit , Dundee , Scotland ) and CRP levels at a later stage .", "label": "", "metadata": {}, "score": "65.035416"}
{"text": "A Double Blind Randomization to Letrozole or Placebo for Women Previously Diagnosed With Primary Breast Cancer Completing Five Years of Adjuvant Aromatase Inhibitor Either as Initial Therapy or After Tamoxifen ( Including Those in The MA.17 Study ) .", "label": "", "metadata": {}, "score": "65.077896"}
{"text": "A detailed description of this register has been reported elsewhere .20 Briefly , consecutive cases of IP are notified through general practitioners or attendance at hospital rheumatology clinics within this catchment area .", "label": "", "metadata": {}, "score": "65.287125"}
{"text": "The table shows the age at time of operation ( for patients without grafts , the time of surgery is taken as May of the year 2000 ; which is the average date of the operations of the first four patients ) along with their disease characteristics .", "label": "", "metadata": {}, "score": "65.34466"}
{"text": "Subject 5 was scanned using a different PET camera and hence , his data could not be compared directly with the rest .The rates of progression of his striatal RAC BP at 1 year post - transplantation were 8.9 % and 7.3 % per annum for the right and left sides respectively .", "label": "", "metadata": {}, "score": "65.37763"}
{"text": "In patients with neovascular AMD , following monthly intravitreal administration of 0.5 mg LUCENTIS , mean ( \u00b1SD ) maximum ranibizumab serum concentrations were 1.7 ( \u00b1 1.1 ) ng / mL. No significant change from baseline was observed in the mean plasma VEGF concentrations following three monthly 0.5 mg intravitreal injections .", "label": "", "metadata": {}, "score": "65.631065"}
{"text": "Sustained clinical remission in rheumatoid arthritis : prevalence and prognostic factors in an inception cohort of patients treated with conventional DMARDS .Rheumatology ( Oxford ) 2012 ; 51 : 169 - 75 . . .", "label": "", "metadata": {}, "score": "65.80355"}
{"text": "For each patient , worst grade of each event type is reported .Compare prostate specific antigen ( PSA ) response rates between the experimental arm and the standard arm .", "label": "", "metadata": {}, "score": "65.84447"}
{"text": "28 , 36 In our analyses , we also confirmed the well established independent association of age , gender , HAQ , CRP , presence of nodules and steroid treatment with mortality .", "label": "", "metadata": {}, "score": "65.93933"}
{"text": "Time to First Skeletal - related Event [ Time Frame :During study period ( up to 3 years ) ] [ Designated as safety issue : No ] .", "label": "", "metadata": {}, "score": "66.155396"}
{"text": "Patients without an event were censored at the last date the patient was known to be disease - free .Recurrence and new occurrence of colorectal cancer were based on tumor assessments made by the investigator .", "label": "", "metadata": {}, "score": "66.25043"}
{"text": "Calculation of statistical power for this study was not based on survival of the native hip to THR , but rather the WOMAC pain subscale , which was the primary outcome measure of this trial .", "label": "", "metadata": {}, "score": "66.31601"}
{"text": "Given orally .Study Arm ( s ) .Experimental : Arm I .Patients receive docetaxel IV over 1 hour on day 1 .Patients also receive oral atrasentan and oral prednisone once daily on days 1 - 21 .", "label": "", "metadata": {}, "score": "66.32994"}
{"text": "Study AMD-3 .Study AMD-3 was a randomized , double - masked , sham - controlled , two - year study designed to assess the safety and efficacy of LUCENTIS in patients with neovascular AMD ( with or without a classic CNV component ) .", "label": "", "metadata": {}, "score": "66.49277"}
{"text": "Correlation between radiographic severity of knee osteoarthritis and future disease progression .Results from a 3-year prospective , placebo - controlled study evaluating the effect of glucosamine sulfate .", "label": "", "metadata": {}, "score": "66.494385"}
{"text": "Serum ranibizumab concentrations in RVO and DME and DR patients were similar to those observed in neovascular AMD patients .Based on a population pharmacokinetic analysis of patients with neovascular AMD , maximum serum concentrations are predicted to be reached at approximately 1 day after monthly intravitreal administration of LUCENTIS 0.5 mg / eye .", "label": "", "metadata": {}, "score": "66.51745"}
{"text": "Time to Prostate - specific Antigen ( PSA )Progression [ Time Frame :During study period ( up to 3 years ) ] [ Designated as safety issue : No ] .", "label": "", "metadata": {}, "score": "66.57417"}
{"text": "This study has some limitations .Due to the study design , we were not able to apply any of the current definitions of remission ( neither dimensional criteria based on specified cut - offs of continuous DASs nor categorical criteria based on fulfilment of prespecified items ) .", "label": "", "metadata": {}, "score": "66.59601"}
{"text": "Patient 1 developed a renal cell carcinoma following the first transplant which was resected with no residual tumour and no metastatic spread .The occurrence of this tumour was thought to be unrelated to either the transplant or immunosuppressive medication , and as such , the patient completed a full course of immunosuppression following the second transplant without any adverse events .", "label": "", "metadata": {}, "score": "66.646225"}
{"text": "Secondary analyses .In order to verify the relevance of a stricter definition of remission on mortality , we tested and compared the effect of two other definitions which were progressively more permissive in terms of residual joint involvement ( see online supplementary table S2 ) .", "label": "", "metadata": {}, "score": "66.84297"}
{"text": "Failed screening in a parent tanezumab double blind CLBP study .Withdrawn from a parent tanezumab double blind CLBP study for an adverse event .Pregnant women , lactating mothers , women suspected of being pregnant , and women who wish to become pregnant during the course of clinical study .", "label": "", "metadata": {}, "score": "66.84509"}
{"text": "In patients with early rheumatoid arthritis , the new ACR / EULAR definition of remission identifies patients with persistent absence of functional disability and suppression of ultrasonographic synovitis .", "label": "", "metadata": {}, "score": "66.85736"}
{"text": "DISEASE CHARACTERISTICS : .Previously diagnosed with primary breast cancer .Must have received 4\u00bd - 6 years of aromatase inhibitor therapy ( e.g. , letrozole , anastrozole , or exemestane ) , either as initial therapy or after prior tamoxifen citrate , including treatment received as part of clinical trial CAN - NCIC - MA17 .", "label": "", "metadata": {}, "score": "67.415405"}
{"text": "20 We sought to investigate the association between early remission according to different definitions with overall survival within the NOAR cohort .Methods .Study design , setting and participants .", "label": "", "metadata": {}, "score": "67.66047"}
{"text": "Patient consent Obtained .Ethics approval The study was approved by the regional medical research ethics committee and was carried out in compliance with the Helsinki Declaration .", "label": "", "metadata": {}, "score": "67.76231"}
{"text": "At baseline , 62 % of patients had NPDR ( ETDRS - RSS less than 60 ) and 31 % had PDR ( ETDRS - RSS greater than or equal to 60 ) .", "label": "", "metadata": {}, "score": "68.164856"}
{"text": "Pisters et al 22 based inclusion on the clinical criteria of the American College of Rheumatology alone , which does not include radiographic evidence of OA .", "label": "", "metadata": {}, "score": "68.44433"}
{"text": "Rheumatology ( Oxford )2004 ; 43 : 1519 - 25 . . .Remission achieved after 2 years treatment with low - dose prednisolone in addition to disease - modifying anti - rheumatic drugs in early rheumatoid arthritis is associated with reduced joint destruction still present after 4 years : an open 2-year continuation study .", "label": "", "metadata": {}, "score": "68.69746"}
{"text": "In patients treated with LUCENTIS , the area of CNV leakage , on average , decreased by Month 3 as assessed by FA .The area of CNV leakage for an individual patient was not correlated with visual acuity .", "label": "", "metadata": {}, "score": "68.70653"}
{"text": "9 - 11 Cut - offs around low disease activity have been identified as relevant predictors of mortality in these studies .In this context , achieving remission is regarded as the most desirable outcome in IP , including RA .", "label": "", "metadata": {}, "score": "69.03247"}
{"text": "Baseline data included age , gender , date of symptom onset and smoking status ( current , ex- and never ) .The American College of Rheumatology ( ACR ) 1987 criteria for RA were applied at baseline and cumulatively .", "label": "", "metadata": {}, "score": "69.071396"}
{"text": "Abstract ] J Clin Oncol 30 ( Suppl 15 ) : A-4511 , 2012 .The purpose of this study is to investigate the safety and efficacy of tanezumab for chronic low back pain .", "label": "", "metadata": {}, "score": "69.076416"}
{"text": "Gender .Female .Ages .Not Provided .Accepts Healthy Volunteers .No .Contacts ICMJE .Contact information is only displayed when the study is recruiting subjects September 2013 ( final data collection date for primary outcome measure ) .", "label": "", "metadata": {}, "score": "69.09932"}
{"text": "J Rheumatol 1988 ; 15 : 1833 - 40 . . .Long - term effectiveness of exercise therapy in patients with osteoarthritis of the hip or knee : a randomized controlled trial comparing two different physical therapy interventions .", "label": "", "metadata": {}, "score": "69.142075"}
{"text": "Original Secondary Outcome Measures ICMJE ( submitted : September 30 , 2010 ) .Time to First Skeletal - related Event .Time to Initiation of Cytotoxic Chemotherapy .", "label": "", "metadata": {}, "score": "69.38576"}
{"text": "No disease related symptoms .Normalization of markers and other abnormal lab values .Partial Response ( PR ) : Applies only to patients with at least one measurable lesion .", "label": "", "metadata": {}, "score": "69.54198"}
{"text": "15 , 23 , 24 THR rates have increased steadily during the past four decades , 25 which in turn has enlarged healthcare costs substantially .", "label": "", "metadata": {}, "score": "69.55504"}
{"text": "Our study had some limitations .The criteria for when THR surgery was indicated were not specified prior to the start of the study .The criteria used for THR at our institution ( night pain and Harris Hip Score below 60 points ) are not necessarily used at other hospitals , and the symptom state may differ at time of surgery .", "label": "", "metadata": {}, "score": "69.57603"}
{"text": "Macular focal / grid laser treatment was given to 26 of 131 ( 20 % ) patients treated with 0.5 mg LUCENTIS and 71 of 132 ( 54 % ) patients treated with sham .", "label": "", "metadata": {}, "score": "69.81656"}
{"text": "Time to discontinuation due to lack of efficacy .[ Time Frame : 56 weeks ] [ Designated as safety issue : No ] .Use of concomitant analgesic medication for CLBP .", "label": "", "metadata": {}, "score": "69.97365"}
{"text": "3 The condition is currently incurable with the patient usually dying within 15 - 30 years of disease onset .Current therapies provide only partial relief of some of the symptoms of HD , and no disease - modifying therapies are yet available .", "label": "", "metadata": {}, "score": "70.02264"}
{"text": "Between 2000 and 2003 , the ' NEST - UK ' consortium carried out bilateral striatal transplants of human fetal striatal tissue in five HD patients .", "label": "", "metadata": {}, "score": "70.42639"}
{"text": "This study was terminated on 30 November 2010 following a US FDA clinical hold for tanezumab chronic low back pain clinical studies which halted dosing and enrollment of patients on 19 July 2010 for potential safety issues .", "label": "", "metadata": {}, "score": "70.4812"}
{"text": "Only patients with measurable soft tissue disease ( ie , at least 1 target lesion identified per RECIST 1.1 ) at screening are included in this analysis .", "label": "", "metadata": {}, "score": "70.50051"}
{"text": "Missing data on confounders were imputed using switching regression , an iterative multivariable regression technique which retains an element of random variation in the estimates .", "label": "", "metadata": {}, "score": "70.55321"}
{"text": "Given that RF was not associated to remission , RF did not modify the effect of remission on mortality in this analysis .Though no significant statistical interactions were found , the protective effect of remission was slightly higher in men , as previously reported in RA .", "label": "", "metadata": {}, "score": "70.65291"}
{"text": "Importantly , no significant adverse or placebo effects were seen .Notably , the raclopride positron emission tomography ( PET ) signal in individuals with transplants , indicated that there was no obvious surviving striatal graft tissue .", "label": "", "metadata": {}, "score": "70.72958"}
{"text": "The particular setting of NOAR allowed us to measure the effect of remission , taking into account several potential confounders , thus providing more precise and less biased measures of association .", "label": "", "metadata": {}, "score": "70.764145"}
{"text": "In hip OA , exercise interventions have shown promising results , 7 - 9 but the need for high - quality clinical trials with sufficient follow - up time is emphasised .", "label": "", "metadata": {}, "score": "70.81772"}
{"text": "Some studies have recommended and used total joint replacement as a hard endpoint in OA , 10 , 27 - 29 but it is debatable whether it can be interpreted as an expression for OA progression .", "label": "", "metadata": {}, "score": "70.93945"}
{"text": "Thirty - five per cent of the patients went through THR surgery at the Oslo University Hospital , and the remaining 65 % went through surgery at 1 of 11 other hospitals in the southern parts of Norway .", "label": "", "metadata": {}, "score": "71.115746"}
{"text": "Known or suspected brain metastasis or active leptomeningeal disease .Contact information is only displayed when the study is recruiting subjects .Listed Location Countries ICMJE .", "label": "", "metadata": {}, "score": "71.19614"}
{"text": "Effect modification was systematically explored by fitting interactions between remission variables and confounders in multivariable models .Proportional hazard assumption was tested by formal tests on Shoenfield residuals .", "label": "", "metadata": {}, "score": "71.27765"}
{"text": "Because the increases in plasma ranibizumab exposures in these patients are not considered clinically significant , no dosage adjustment is needed based on renal impairment status .", "label": "", "metadata": {}, "score": "71.31999"}
{"text": "OBJECTIVES : . Primary .To compare the disease - free survival of women with primary breast cancer treated with letrozole vs placebo after completing approximately 5 years ( i.e. , 4\u00bd - 6 years ) of aromatase inhibitor therapy ( e.g. , letrozole , anastrozole , or exemestane ) .", "label": "", "metadata": {}, "score": "71.845345"}
{"text": "15 Despite the lack of power of this study , mainly due to the low number of events in the remission group , these data support a tendency toward a better outcome in patients with a persistent status of remission , as our data show .", "label": "", "metadata": {}, "score": "71.86052"}
{"text": "For general information , see Learn About Clinical Studies .Please refer to this study by its ClinicalTrials.gov identifier : NCT00924664 Current Secondary Outcome Measures ICMJE ( submitted : August 3 , 2011 ) .", "label": "", "metadata": {}, "score": "71.866745"}
{"text": "Measured from date of registration to date of first observation of progressive disease , or death due to any cause .Patients without progression are censored at date of last contact .", "label": "", "metadata": {}, "score": "71.96867"}
{"text": "[ 2 ] .Other relevant method information , such as adjustments or degrees of freedom : .[ 3 ] .Additional information , such as whether or not the p - value is adjusted for multiple comparisons and the a priori threshold for statistical significance : .", "label": "", "metadata": {}, "score": "71.982376"}
{"text": "The bold line indicates the best fit linear regression applied to the five transplant cases ( solid ) and separately to the 12 controls ( dashed ) .", "label": "", "metadata": {}, "score": "72.064705"}
{"text": "14 All the remission definitions and variables are summarised in O table 1 .All patients were flagged with the Office for National Statistics and followed up from the date of symptom onset to date of death , embarkation date or 1 May 2011 , whichever came first .", "label": "", "metadata": {}, "score": "72.20677"}
{"text": "Steady - state minimum concentration is predicted to be 0.22 ng / mL with a monthly dosing regimen .In humans , serum ranibizumab concentrations are predicted to be approximately 90,000-fold lower than vitreal concentrations .", "label": "", "metadata": {}, "score": "72.27757"}
{"text": "Primary Purpose : Treatment .Official Title : .A Randomized , Multicenter , Long Term Study of the Safety of Tanezumab in Patients With Chronic Low Back Pain .", "label": "", "metadata": {}, "score": "72.49902"}
{"text": "The best overall soft tissue objective response is defined as partial response [ PR ] or complete response [ CR ] while on study treatment based on investigator assessments of target , nontarget , and new lesions using RECIST 1.1 .", "label": "", "metadata": {}, "score": "72.54751"}
{"text": "Effect of leisure time physical activity on severe knee or hip osteoarthritis leading to total joint replacement : a population - based prospective cohort study .", "label": "", "metadata": {}, "score": "72.75444"}
{"text": "Our findings are applicable for patients with symptomatic and radiographic hip OA , with mild to moderate symptoms .Patients with severe symptoms and patients with knee or back pain were excluded .", "label": "", "metadata": {}, "score": "72.81708"}
{"text": "Efficacy of patient education and supervised exercise vs patient education alone in patients with hip osteoarthritis : a single blind randomized clinical trial .Osteoarthritis Cartilage 2010 ; 18 : 1237 - 43 . . .", "label": "", "metadata": {}, "score": "73.31154"}
{"text": "At Month 12 , the mean change in the total area of the CNV lesion was 0.1 - 0.3 disc areas ( DA ) for LUCENTIS versus 2.3 - 2.6 DA for the control arms .", "label": "", "metadata": {}, "score": "73.34573"}
{"text": "Remission was defined as absence of clinically detectable joint inflammation on a 51-joint count .In sensitivity analyses , less stringent definitions of remission were used , based on 28-joint counts .", "label": "", "metadata": {}, "score": "73.82349"}
{"text": "OBJECTIVES : .Primary .Compare the survival and progression - free survival of patients with hormone - refractory stage IV prostate cancer and bone metastases treated with docetaxel and prednisone combined with either atrasentan vs placebo .", "label": "", "metadata": {}, "score": "73.926605"}
{"text": "TD - OCT measurements were collected at baseline , Months 1 , 2 , 3 , 5 , 8 , and 12 .In patients treated with LUCENTIS , CPT decreased , on average , more than in the sham group from baseline through Month 12 .", "label": "", "metadata": {}, "score": "74.029854"}
{"text": "Menopausal status not specified .ECOG performance status 0 - 2 .Able ( i.e. sufficiently fluent ) and willing to complete quality - of - life questionnaires in either English or French ( NCIC CTG participating centers ) .", "label": "", "metadata": {}, "score": "74.04842"}
{"text": "Censoring was set at 1 May 2011 .The effect of remission on mortality was analysed using the Cox proportional hazard regression model , and presented as HRs and 95 % CIs .", "label": "", "metadata": {}, "score": "74.11897"}
{"text": "Compare progression - free survival between a control or standard therapy arm of docetaxel + placebo + prednisone with docetaxel + atrasentan + prednisone in patients with hormone refractory prostate cancer .", "label": "", "metadata": {}, "score": "74.13934"}
{"text": "Other : placebo .Goldkorn A , Ely B , Quinn DI , et al .: Results of telomerase activity measurements from live circulating tumor cells captured on a slot microfilter in a phase III SWOG - coordinated prostate cancer trial ( S0421 ) .", "label": "", "metadata": {}, "score": "74.21692"}
{"text": "The Genstat analysis programme is powered to estimate missing values by an iterative minimum variance routine that reduces the degrees of freedom in the estimates of error variance to correct for regression towards the mean , allowing unbiased inclusion of all patients ' data .", "label": "", "metadata": {}, "score": "74.487915"}
{"text": "Alternatively , the absence of a convincing increase here in the post - transplantation striatal raclopride signal could relate more to the fact that we simply did not implant sufficient numbers of cells , a major determinant of the survival and differentiation of striatal grafts .", "label": "", "metadata": {}, "score": "74.52614"}
{"text": "An end - result study using a new method of result evaluation .J Bone Joint Surg Am 1969 ; 51 : 737 - 55 . . .", "label": "", "metadata": {}, "score": "75.0432"}
{"text": "All authors revised and approved the final manuscript .MAR acts as a guarantor for this study .Funding This study was supported by grants from the former science council at Ullevaal University Hospital , Oslo , and the EXTRA funds from the Norwegian Foundation for Health and Rehabilitation , through the Norwegian Rheumatism Association .", "label": "", "metadata": {}, "score": "75.83336"}
{"text": "UHDRS total motor score .The total UHDRS motor score of the five patients with transplants was compared with that of the 12 patients without grafts .", "label": "", "metadata": {}, "score": "75.98488"}
{"text": "A Multinational Phase 3 , Randomized , Double - Blind , Placebo - Controlled Efficacy and Safety Study of Oral MDV3100 in Chemotherapy - Naive Patients With Progressive Metastatic Prostate Cancer Who Have Failed Androgen Deprivation Therapy .", "label": "", "metadata": {}, "score": "76.00485"}
{"text": "Among adjusting variables , effect modifiers have been previously described .In NOAR , excess mortality was confined to patients who were RF positive .33 Also , the effect of high DAS28 on mortality was slightly higher in men ( HR 1.58 ) than in women ( HR 1.21 ) .", "label": "", "metadata": {}, "score": "76.17785"}
{"text": "Interacting these two variables we found that the lowest risk of death was associated with the earliest and most persistent status of remission .This might be due to the overall exposure to active inflammatory process , which is regarded as the main cause of premature mortality in IP .", "label": "", "metadata": {}, "score": "76.704926"}
{"text": "10 - 14 It is unknown whether exercise therapy can influence the progression of OA and thereby reduce the need for total joint replacement .The main objective of this study was therefore to evaluate the long - term effect of exercise therapy in addition to patient education on the patient 's need for total hip replacement ( THR ) .", "label": "", "metadata": {}, "score": "76.70798"}
{"text": "Prostate Cancer .Intervention ICMJE .Drug : Enzalutamide .Participants received enzalutamide 160 mg , administered as four 40-mg capsules , once per day by mouth .", "label": "", "metadata": {}, "score": "76.9554"}
{"text": "OARSI recommendations for the management of hip and knee osteoarthritis : part III : Changes in evidence following systematic cumulative update of research published through January 2009 .", "label": "", "metadata": {}, "score": "77.652985"}
{"text": "Evaluation of the structure - modifying effects of diacerein in hip osteoarthritis : ECHODIAH , a three - year , placebo - controlled trial .Evaluation of the Chondromodulating Effect of Diacerein in OA of the Hip .", "label": "", "metadata": {}, "score": "77.69845"}
{"text": "Radiographic disease progression in bone required a confirmatory scan .Radiographic disease progression in soft tissue did not require a confirmatory scan for purposes of analysis .", "label": "", "metadata": {}, "score": "77.73578"}
{"text": "PASE is a brief , self - administered , 7-day recall questionnaire to assess physical activity in older adults .The Norwegian version was used , which consisted of 24 questions giving a total score ranging from 0 to 315 .", "label": "", "metadata": {}, "score": "77.77977"}
{"text": "PET .As the first four surgical subjects received implantation into the right striatum initially , their left striatal binding potential ( BP ) acted as an internal control for the contralateral side prior to the second implantation .", "label": "", "metadata": {}, "score": "77.90311"}
{"text": "MAR was responsible for the project funding .LN and LF contributed to clinical screening of participants and LN assessed all radiographs .LF and IS carried out the outcome assessments .", "label": "", "metadata": {}, "score": "78.05528"}
{"text": "Measured Values . FOLFOX4 . FOLFOX4 + Bv .XELOX+Bv .Disease - free Survival in Stage III Cancer Patients - Time to Event [ units : months ] Median ( 95 % Confidence Interval ) .", "label": "", "metadata": {}, "score": "78.08734"}
{"text": "Lucentis .\" If you 've ever been sleep - deprived , you 've probably had a firsthand glimpse of the blood vessels in your eyes .", "label": "", "metadata": {}, "score": "78.09241"}
{"text": "ClinicalTrials.gov number NCT00319423 ( original project protocol ) and NCT01338532 ( additional protocol for long - term follow - up ) .Introduction .Physical activity and patient information is recommended for all patients with osteoarthritis ( OA ) of the hip and knee as first - line treatment .", "label": "", "metadata": {}, "score": "78.10348"}
{"text": "12 It is debatable whether postponing surgery is beneficial for the patients in the long term .36 , 37 We argue that for patients with tolerable pain who are able to maintain their desired activity level and who are relatively young postponing surgery is appropriate and may reduce the future need for THR or repetitive THR revision surgery .", "label": "", "metadata": {}, "score": "78.266685"}
{"text": "February 2016 ( final data collection date for primary outcome measure ) .Current Primary Outcome Measures ICMJE ( submitted : February 24 , 2014 ) .", "label": "", "metadata": {}, "score": "79.340096"}
{"text": "Increased retinal thickness ( i.e. , center point thickness ( CPT ) or central foveal thickness ( CFT ) ) , as assessed by optical coherence tomography ( OCT ) is associated with neovascular AMD , macular edema following RVO , and DME .", "label": "", "metadata": {}, "score": "79.46091"}
{"text": "At the same time , attention still needs to be paid to accurate tissue dissection , since misdissection to include any meningeal cells can yield clear overgrowth and proliferation of non - neuronal tissues within neural grafts .", "label": "", "metadata": {}, "score": "79.75911"}
{"text": "THR in the index joint was defined as event , while patients who were lost to follow - up , were dead or were followed until the end of study were treated as censored in the analysis .", "label": "", "metadata": {}, "score": "79.81558"}
{"text": "Abstract .Background Exercise treatment is recommended for all patients with hip osteoarthritis ( OA ) , but its effect on the long - term need for total hip replacement ( THR ) is unknown .", "label": "", "metadata": {}, "score": "79.970375"}
{"text": "Since less stringent criteria also included subjects fulfilling more stringent criteria , we used contrasts to separate the single effect of each definition ( table 5 ) .", "label": "", "metadata": {}, "score": "80.33942"}
{"text": "The FACT - P also addresses four general domains of QOL ( physical , functional , emotional , and social well - being subscales ) as well as symptom concerns associated with prostate cancer and its treatment .", "label": "", "metadata": {}, "score": "80.49594"}
{"text": "MRI .Postoperative MRI scans confirmed appropriate surgical targeting with increased FLAIR signal along the implantation tracts .No occult haemorrhage was identified .Subsequent imaging was unable to identify any implanted material , and there were no mass lesions seen to develop in or around the transplant site .", "label": "", "metadata": {}, "score": "80.675995"}
{"text": "Patient 4 was unable to attend further appointments after 2005 , 2 years after his second transplant .He died on 25 December 2009 ; the cause of death was recorded as aspiration pneumonia .", "label": "", "metadata": {}, "score": "80.90863"}
{"text": "Comparison with the preliminary American College of Rheumatology and the World Health Organization / International League Against Rheumatism Criteria .Arthritis Rheum 1996 ; 39 : 34 - 40 . . .", "label": "", "metadata": {}, "score": "81.33003"}
{"text": "Unless otherwise noted , visual acuity was measured at a distance of 4 meters .Neovascular ( Wet ) Age - Related Macular Degeneration ( AMD ) .", "label": "", "metadata": {}, "score": "81.982666"}
{"text": "Current Other Outcome Measures ICMJE .Not Provided .Original Other Outcome Measures ICMJE .Not Provided .Descriptive Information .Brief Title ICMJE .Letrozole in Treating Women With Primary Breast Cancer Who Have Received 5 Years of Aromatase Inhibitor Therapy .", "label": "", "metadata": {}, "score": "82.05899"}
{"text": "OUTLINE : This is a randomized , double - blind , placebo - controlled , multicenter study .Patients are randomized to 1 of 2 treatment arms .", "label": "", "metadata": {}, "score": "82.40587"}
{"text": "22 The UK arm of this program was established as a collaboration between six centres ( NEST - UK : Belfast , Aberdeen , Manchester , Cardiff , Cambridge , London ) coordinated from Cambridge , with recruitment into the longitudinal assessment cohort taking place from 1994 to 2000 .", "label": "", "metadata": {}, "score": "82.58765"}
{"text": "Of the 759 patients enrolled , 746 patients had a baseline assessment of fundus photography .Patients had baseline Early Treatment Diabetic Retinopathy Study ( ETDRS )", "label": "", "metadata": {}, "score": "82.683075"}
{"text": "Drug : prednisone .Active Comparator : Arm II .Patients receive docetaxel and prednisone as in arm I. Patients also receive oral placebo once daily on days 1 - 21 .", "label": "", "metadata": {}, "score": "82.939606"}
{"text": ": SWOG S0421 : phase III study of docetaxel ( D ) and atrasentan ( A ) versus docetaxel and placebo ( P ) for men with advanced castrate resistant prostate cancer ( CRPC ) .", "label": "", "metadata": {}, "score": "83.05522"}
{"text": "Study Design ICMJE .Allocation : Randomized Intervention Model : Parallel Assignment Masking : Double Blind ( Subject , Caregiver , Investigator )Primary Purpose : Treatment .", "label": "", "metadata": {}, "score": "83.18106"}
{"text": "PURPOSE : This randomized phase III trial is studying letrozole to see how well it works compared with a placebo in treating women with primary breast cancer who have received 5 years of aromatase inhibitor therapy .", "label": "", "metadata": {}, "score": "83.84076"}
{"text": "Not Provided .Current Other Outcome Measures ICMJE .Not Provided .Original Other Outcome Measures ICMJE .Not Provided .Descriptive Information .Brief Title ICMJE . S0421 , Docetaxel and Prednisone With or Without Atrasentan in Treating Patients With Stage IV Prostate Cancer and Bone Metastases That Did Not Respond to Previous Hormone Therapy .", "label": "", "metadata": {}, "score": "83.84564"}
{"text": "Nevertheless , as already demonstrated against functional disability , this lack of complete content validity does not affect the predictive validity of our definitions of remission .", "label": "", "metadata": {}, "score": "83.95794"}
{"text": "Htt is now recognised to be involved in a variety of cellular , metabolic , transcription and maintenance processes throughout development and in the adult . 1 , 2 Abnormal CAG expansion in HD results in neuronal dysfunction , aberrant intracellular aggregation of mutant protein fragments and , eventually , cell death .", "label": "", "metadata": {}, "score": "84.03657"}
{"text": "Early functional disability predicts both all - cause and cardiovascular mortality in people with inflammatory polyarthritis : results from the Norfolk Arthritis Register .Ann Rheum Dis 2007 ; 66 : 486 - 92 . . .", "label": "", "metadata": {}, "score": "84.08525"}
{"text": "Not Provided .Original Other Outcome Measures ICMJE .Not Provided .Descriptive Information .Brief Title ICMJE .A Safety and Efficacy Study of Oral MDV3100 in Chemotherapy - Naive Patients With Progressive Metastatic Prostate Cancer .", "label": "", "metadata": {}, "score": "84.43299"}
{"text": "Roland Morris Disability Questionnaire ( RMDQ ) total score , Patient Global Assessment of Low Back Pain , and Work Productivity and Activity Impairment Questionnaire total score change from Baseline to various time points throughout the study .", "label": "", "metadata": {}, "score": "84.442215"}
{"text": "The NEST - UK multicentre study was initiated in 1998 as the second of two European centres to evaluate the safety and efficacy of bilateral fetal striatal transplantation in HD ( ISRCTN no 36485475 ) .", "label": "", "metadata": {}, "score": "84.62492"}
{"text": "Accessible for treatment and follow - up .PRIOR CONCURRENT THERAPY : .See Disease Characteristics .No concurrent selective estrogen receptor modulator ( e.g. , raloxifene , idoxifene ) .", "label": "", "metadata": {}, "score": "84.646225"}
{"text": "Microvascular retinal changes and neovascularization , as assessed by color fundus photography , are associated with diabetic retinopathy .Neovascular ( Wet ) Age - Related Macular Degeneration .", "label": "", "metadata": {}, "score": "84.6703"}
{"text": "A Cox proportional hazard model was used to calculate HR and 95 % CI between groups .No adjusted analysis was conducted due to equality of groups at baseline .", "label": "", "metadata": {}, "score": "84.70892"}
{"text": "To compare the effect of these drugs on overall ( all cause specific ) mortality of these patients .To compare the incidence of contralateral breast cancer in patients treated with these drugs .", "label": "", "metadata": {}, "score": "84.897285"}
{"text": "Choosing to participate in a study is an important personal decision .Talk with your doctor and family members or friends about deciding to join a study .", "label": "", "metadata": {}, "score": "85.80316"}
{"text": "Agree with manuscript results and conclusions : CAS , SMMV , DPMS , ML and TM .Funding NOAR is funded as part of the core programme grant to the Arthritis Research UK Epidemiology Unit ( Grant reference 17552 ) .", "label": "", "metadata": {}, "score": "86.15492"}
{"text": "5 NIHR Manchester Musculoskeletal Biomedical Research Unit , Manchester , UK .Abstract .Objectives This study aimed to evaluate whether the early achievement of clinical remission influences overall survival in an inception cohort of patients with inflammatory polyarthritis ( IP ) .", "label": "", "metadata": {}, "score": "86.4619"}
{"text": "13 - 15 Such results are highly consistent throughout the literature , despite quite different definitions of remission being applied .14Although recently a new definition of remission was proposed , a fully valid definition of remission for RA is still not available , even though the most stringent ones seem to be better in terms of predicting long - term outcomes .", "label": "", "metadata": {}, "score": "86.64151"}
{"text": "ER+ and/or PR+ primary tumor OR hormone receptor status of primary tumor unknown ( for patients previously enrolled on clinical trial CAN - NCIC - MA17 ) .", "label": "", "metadata": {}, "score": "86.72589"}
{"text": "Directive 2004/23/EC of 31 March 2004 , On setting standards of quality and safety for the donation , procurement , testing , processing , preservation , storage and distribution of human tissue and cells .", "label": "", "metadata": {}, "score": "87.694"}
{"text": "The binding of ranibizumab to VEGF - A prevents the interaction of VEGF - A with its receptors ( VEGFR1 and VEGFR2 ) on the surface of endothelial cells , reducing endothelial cell proliferation , vascular leakage , and new blood vessel formation .", "label": "", "metadata": {}, "score": "88.91249"}
{"text": "Not Provided .Study Type ICMJE .Interventional .Study Phase .Phase 3 .Study Design ICMJE .Allocation : Randomized Intervention Model : Parallel Assignment Masking : Double Blind ( Subject , Investigator , Outcomes Assessor ) Primary Purpose : Treatment .", "label": "", "metadata": {}, "score": "89.08554"}
{"text": "Lucentis .CLINICAL PHARMACOLOGY .Mechanism Of Action .Ranibizumab binds to the receptor binding site of active forms of VEGF -A , including the biologically active , cleaved form of this molecule , VEGF110 .", "label": "", "metadata": {}, "score": "89.269806"}
{"text": "The following authors were involved in drafting and/or revising the manuscript : RAB , SLM , TPH , RAS , PP , YFT , DJB , PN , WC , AER , SBD .", "label": "", "metadata": {}, "score": "89.29216"}
{"text": "The purpose of this study is to determine the benefit of enzalutamide versus placebo as assessed by overall survival and progression - free survival in patients with progressive metastatic prostate cancer who have failed androgen deprivation therapy but not yet received chemotherapy .", "label": "", "metadata": {}, "score": "89.717224"}
{"text": "Implementation of the tissue directive into UK regulation led to suspension of the NEST - UK trial , pending full compliance with the new European standards , and this process is still ongoing .", "label": "", "metadata": {}, "score": "93.04999"}
{"text": "A skeletal - related event was defined as radiation therapy or surgery to bone for prostate cancer , pathological bone fracture , spinal cord compression , or initiation / change in antineoplastic therapy to treat bone pain from prostate cancer .", "label": "", "metadata": {}, "score": "93.34254"}
{"text": "Thanks to Sonya Foley for her help in an early draft of this paper .We would also like to acknowledge the NIHR support for the Biomedical Research Centre at Addenbrooke 's Hospital and the University of Cambridge .", "label": "", "metadata": {}, "score": "94.86791"}
{"text": "Abstract .Huntington 's disease ( HD ) is a fatal autosomal dominant neurodegenerative disease involving progressive motor , cognitive and behavioural decline , leading to death approximately 20 years after motor onset .", "label": "", "metadata": {}, "score": "95.086914"}
{"text": "Introduction .Patients with inflammatory polyarthritis ( IP ) , and its subset rheumatoid arthritis ( RA ) , have an increased mortality risk compared with the general population . 1 For this reason , mortality should be regarded as one of the most important long - term outcomes of the management of IP . 1 - 5 Acute phase reactants , including both erythrocyte sedimentation rate and C reactive protein ( CRP ) , have also been strongly linked to increased risk of death , mainly from cardiovascular causes .", "label": "", "metadata": {}, "score": "95.18535"}
{"text": "Acknowledgments .The authors would like to acknowledge the contribution of the NOAR staff and metrologists .We are also grateful to the GPs and rheumatologists of the former Norwich Health Authority for their dedication in referring patients to the register .", "label": "", "metadata": {}, "score": "95.44136"}
{"text": "Phase III Study of Docetaxel and Atrasentan Versus Docetaxel and Placebo for Patients With Advanced Hormone Refractory Prostate Cancer .Brief Summary .RATIONALE : Drugs used in chemotherapy , such as docetaxel , prednisone , and atrasentan work in different ways to stop the growth of tumor cells , either by killing the cells or by stopping them from dividing .", "label": "", "metadata": {}, "score": "96.0776"}
{"text": "Wrote the first draft of the manuscript : CAS .Contributed to the writing of the manuscript : CAS , SMMV , DPMS , ML and TM .", "label": "", "metadata": {}, "score": "96.613205"}
{"text": "RAB and SLM joint first authors .Contributors The following authors were involved in the concept and design of the study : RAB , TPH , BJS , PP , DJB , WC , AER , SBD and the NEST - UK collaboration .", "label": "", "metadata": {}, "score": "96.826164"}
{"text": "Not Provided .Active , not recruiting .Enrollment ICMJE .Estimated Completion Date .November 2017 .Estimated Primary Completion Date .July 2017 ( final data collection date for primary outcome measure ) .", "label": "", "metadata": {}, "score": "97.34508"}
{"text": "RATIONALE : Estrogen can cause the growth of breast cancer cells .Hormone therapy using letrozole may fight breast cancer by lowering the amount of estrogen the body makes .", "label": "", "metadata": {}, "score": "98.609344"}
{"text": "Handling editor Tore K Kvien .Contributors Conceived and designed the experiments : DPMS , ML , SMMV and CAS .Performed the experiments : TM .", "label": "", "metadata": {}, "score": "98.85869"}
{"text": "Adjunctive use of the non - ionic surfactant Poloxamer 188 improves fetal dopaminergic cell survival and reinnervation in a neural transplantation strategy for Parkinson 's disease .", "label": "", "metadata": {}, "score": "99.851585"}
{"text": "Abstract ] J Clin Oncol 30 ( Suppl 15 ) : A-4663 , 2012 .[Abstract ] J Clin Oncol 30 ( Suppl 15 ) : A-4547 , 2012 .", "label": "", "metadata": {}, "score": "100.21695"}
{"text": "In patients with bilateral hip OA , the most painful hip was defined as the index joint .Night pain and Harris Hip Score below 60 are used as criteria for THR at our institution .", "label": "", "metadata": {}, "score": "100.33399"}
{"text": "Exclusion criteria were THR in the index joint , knee pain or knee OA , low back pain , rheumatoid arthritis , osteoporosis , cancer , cardiovascular disease unable to tolerate exercise , dysfunction in lower extremities due to accident or disease , pregnancy and not understanding Norwegian .", "label": "", "metadata": {}, "score": "100.69826"}
{"text": "Competing interests None .Ethics approval Cambridge Research Ethics Committee .Provenance and peer review Not commissioned ; externally peer reviewed .Data sharing statement All data relating to this study has been included in the publication .", "label": "", "metadata": {}, "score": "100.87486"}
{"text": "Disclaimer The views expressed are those of the authors .Competing interests None .Patient consent Obtained .Ethics approval Norfolk and Norwich University Hospital Local Research Ethics Committee .", "label": "", "metadata": {}, "score": "102.79958"}
{"text": "Arthritis Rheum 2005 ; 52 : 2293 - 9 . . .Reduction of long - term disability in inflammatory polyarthritis by early and persistent suppression of joint inflammation : results from the Norfolk Arthritis Register .", "label": "", "metadata": {}, "score": "103.96172"}
{"text": "Given orally .Drug : docetaxel .Docetaxel given IV and prednisone given orally .Drug : prednisone .Docetaxel given IV and prednisone given orally .", "label": "", "metadata": {}, "score": "104.63564"}
{"text": "5 NIHR Manchester Musculoskeletal Biomedical Research Unit , Manchester , UK .Accepted 12 May 2013 .Published Online First 7 June 2013 .Abstract .", "label": "", "metadata": {}, "score": "104.89577"}
{"text": "It is not yet known whether docetaxel , prednisone , and atrasentan are more effective than docetaxel and prednisone in treating prostate cancer .PURPOSE : This randomized phase III trial is studying docetaxel , prednisone , and atrasentan to see how well they work compared to docetaxel and prednisone in treating patients with stage IV prostate cancer and bone metastases that did not respond to previous hormone therapy .", "label": "", "metadata": {}, "score": "106.99767"}
{"text": "Acknowledgments .The Norwegian Sports Medicine Clinic ( NIMI ) , Oslo , Norway , is acknowledged for supporting the Norwegian Research Center for Active Rehabilitation with rehabilitation facilities and research staff .", "label": "", "metadata": {}, "score": "107.46705"}
{"text": "Huntington 's disease ( HD ) is an inherited , progressive neurodegenerative disorder characterised by involuntary movements , psychiatric and cognitive symptoms and signs .It is caused by an expansion of the CAG repeat in exon 1 of the huntingtin ( htt ) gene .", "label": "", "metadata": {}, "score": "110.15063"}
{"text": "Handling editor Tore K Kvien .Correction notice This article has been corrected since it was published Online First .The affiliation of the last author has been corrected .", "label": "", "metadata": {}, "score": "116.51582"}
{"text": "Breast Cancer .Intervention ICMJE .Drug : letrozole .Given orally .Other Name : femara .Other : placebo .Given orally .Other Name : sugar pill .", "label": "", "metadata": {}, "score": "117.91913"}
